External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for ...

One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which ...

Evan Y. Yu, MD, discusses other ongoing investigations exploring combinations based on radium-223 (Ra-223), highlighting ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...